PTC Therapeutics, Inc.
PTCT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001070081
In the last 90 days, PTC Therapeutics, Inc. insiders filed 0 open-market purchases and 11 sales; 382 institutions reported holding it in 13F filings for Q2 2026, worth $8.20B in total; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in PTC Therapeutics, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 183
- −24 vs. Q1 2021
- Shares held
- 74.2M
- +36.2K (0.0%) vs. Q1 2021
- Total value
- $3.13B
- −$391.1M (−11.1%) vs. Q1 2021
- New holders
- 16
- 85 more added
- Sold out
- 40
- 50 more reduced
1 institution that held it in Q1 2021 haven't filed for Q2 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PTCT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 382 | $8.20B |
| Q1 2026 | 352 | $6.51B |
| Q4 2025 | 353 | $7.04B |
| Q3 2025 | 294 | $5.07B |
| Q2 2025 | 284 | $3.90B |
| Q1 2025 | 261 | $4.02B |
| Q4 2024 | 240 | $3.51B |
| Q3 2024 | 203 | $2.93B |
| Q2 2024 | 199 | $2.44B |
| Q1 2024 | 184 | $2.48B |
| Q4 2023 | 174 | $2.33B |
| Q3 2023 | 181 | $1.83B |
| Q2 2023 | 206 | $3.30B |
| Q1 2023 | 203 | $3.81B |
| Q4 2022 | 203 | $2.94B |
| Q3 2022 | 213 | $3.83B |
| Q2 2022 | 182 | $2.97B |
| Q1 2022 | 184 | $2.76B |
| Q4 2021 | 179 | $3.00B |
| Q3 2021 | 184 | $2.77B |
| Q2 2021 | 183 | $3.13B |
| Q1 2021 | 208 | $3.52B |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding PTC Therapeutics, Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −13,066−100.0% | Sold out |
| Ameriprise Financial Inc | 0 | $0 | 0.00% | −11,807−100.0% | Sold out |
| Centiva Capital, LP | 0 | $0 | 0.00% | −11,607−100.0% | Sold out |
| Migdal Insurance & Financial Holdings Ltd. | 0 | $0 | 0.00% | −10,571−100.0% | Sold out |
| Cna Financial Corp | 0 | $0 | 0.00% | −10,190−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −8,540−100.0% | Sold out |
| Blueshift Asset Management, LLC | 0 | $0 | 0.00% | −8,468−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −8,227−100.0% | Sold out |
| Bridgefront Capital, LLC | 0 | $0 | 0.00% | −6,634−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −6,271−100.0% | Sold out |
| Engineers Gate Manager LP | 0 | $0 | 0.00% | −5,660−100.0% | Sold out |
| Los Angeles Capital Management LLC | 0 | $0 | 0.00% | −5,332−100.0% | Sold out |
| Creative Planning | 0 | $0 | 0.00% | −5,105−100.0% | Sold out |
| AQR Capital Management LLC | 0 | $0 | 0.00% | −4,583−100.0% | Sold out |
| Pacer Advisors, Inc. | 0 | $0 | 0.00% | −1,327−100.0% | Sold out |
| Brown Brothers Harriman & Co | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Wealthcare Advisory Partners LLC | 0 | $0 | 0.00% | −390−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −207−100.0% | Sold out |
| Assetmark, Inc | 0 | $0 | 0.00% | −42−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −22−100.0% | Sold out |
| Institutional & Family Asset Management, LLC | 0 | $0 | 0.00% | −11−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −16−100.0% | Sold out |
| Meridian Wealth Partners, LLC | 0 | $0 | 0.00% | −11−100.0% | Sold out |
| Amundi Asset Management US, Inc. | – | – | – | – | Not filed |